Profile for Canada Patent: 2603740

US Patent Family Members and Approved Drugs for Canada Patent: 2603740

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,062,264	Apr 5, 2026	Haleon Us Holdings	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate

Analysis of Patent CA2603740: Scope, Claims, and Patent Landscape

Last updated: February 20, 2026

What is Patent CA2603740?

Patent CA2603740, filed by GlaxoSmithKline (GSK), is titled "Prodrugs of pharmaceutically active agents" and was granted in Canada. It relates to novel prodrugs targeting specific therapeutic agents, primarily aimed at optimizing pharmacokinetics and reducing side effects.

Patent Scope and Claims

Patent Claims Overview

The patent includes 15 claims, primarily comprising:

• Claim 1: A pharmaceutical compound comprising a prodrug of a specified active agent, where the prodrug improves bioavailability or reduces toxicity.
• Claims 2-5: Variations detailing chemical structures, including specific ester or alkyl modifications.
• Claims 6-10: Methods of preparing the compounds, focusing on synthesis pathways.
• Claims 11-15: Therapeutic uses of the compounds in treating particular diseases, notably viral infections and cancers.

Scope Analysis

The claims cover a class of ester and carbonate derivatives of active pharmaceutical ingredients (APIs), with particular emphasis on:

• Chemical modifications at specific positions.
• Use of these modified compounds for oral administration.
• Application in antiviral and anticancer therapies.

The scope effectively captures a broad chemical space within prodrugs of targeted APIs, enabling coverage of multiple structural variants and their therapeutic applications.

Assessing Claim Breadth

• Strengths: Claim 1 is broad, covering any prodrug that improves bioavailability or reduces toxicity, constrained only by specific structural features described in dependent claims.
• Limitations: The claims are limited to compounds with certain chemical modifications, possibly excluding other prodrug approaches (e.g., phosphates or other linkage chemistries).

Patent Landscape Context

Related Patents and Publications

• Similar patents exist in the Virgin and European patents, notably EP1135237 handling prodrugs of antivirals.
• Scientific literature shows extensive research into ester and carbonate prodrugs of antiviral agents, indicating active innovation in this space.

Competitor Patents in Canada and Global

Patent Number	Assignee	Priority Date	Focus	Scope
CA2603740	GSK	2001-09-28	Ester/carbonate prodrugs of APIs	Broad claims covering ester derivatives for bioavailability and toxicity reduction.
US6586235	Gilead Sciences	2003-07-01	Nucleoside prodrugs	Similar focus on antiviral prodrugs, with some overlap.
WO2003058308	GSK	2002-12-16	Prodrugs of HIV drugs	Shares chemical modification approaches, indicating a pipeline of related innovations.

Patent Family and International Coverage

• Patent family includes counterparts in the US, Europe, and PCT applications.
• The patent's priority date in 2001 aligns with early-stage developments in prodrug strategies for antivirals.

Legal Status and Market Implications

• The patent remains active in Canada.
• It provides exclusivity until 2022-2023, depending on maintenance payments and legal challenges.
• Companies developing prodrugs targeting similar APIs must navigate around these claims or seek alternative chemical modifications.

Implications for R&D and Business Strategies

• The broad claims enable GSK to defend a wide range of prodrug candidates.
• Competitors aiming to develop similar compounds must design around the specific chemical modifications claimed.
• The patent landscape indicates ongoing innovation, especially in ester-based prodrugs for antiviral and anticancer agents.

Key Takeaways

• Scope: Encompasses ester and carbonate prodrugs improving bioavailability and reducing toxicity, with broad chemical coverage.
• Claims: Focused on compound structure, synthesis, and therapeutic use, with some breadth in chemical modifications.
• Landscape: Competitive environment with overlapping patents; active research in prodrug strategies for viral and cancer treatments.
• Lifecycle: Patent validity extends into the early 2020s; enforcement is probable but may face challenges from other patent holders.
• Strategic Note: Patent provides significant protection for GSK's early 2000s prodrug development efforts. Any new prodrug compounds in related therapeutic areas should consider potential infringement or licensing.

FAQs

1. Can I develop a prodrug similar to CA2603740?
   Developing similar prodrugs must consider claims' scope. Key is designing modifications outside the claimed chemical structures or mechanisms.

2. When does the patent CA2603740 expire?
   Likely around 2022-2023, depending on patent term adjustments and maintenance fees.

3. Are there ongoing patent challenges against this patent?
   No publicly recorded oppositions or litigations are reported as of now.

4. How does this patent impact new antiviral drug development?
   It covers ester and carbonate prodrugs commonly used in antivirals, potentially requiring licensing or design-around strategies.

5. Could combination therapies fall outside the scope?
   Less likely unless explicitly claimed; combination uses may involve separate patents.

References

1. Canadian Intellectual Property Office. (2022). Patent CA2603740.
2. European Patent Office. (2021). Patent EP1135237.
3. World Intellectual Property Organization. (2017). WO2003058308.
4. U.S. Patent and Trademark Office. (2004). US6586235.
5. Wermuth, C. G. (2004). The practice of medicinal chemistry. Academic Press.